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Abstract:  4-Oxo-4H-quinolizine-3-carboxylic acid derivatives bearing sulfamido, 
carboxylamido, benzimidazole and benzothiazole substituents have been designed and 
synthesized. The structures of these new compounds were confirmed by 
1H-NMR, 
13C- 
NMR, IR and ESI (or HRMS) spectra. Compounds were screened for possible HIV 
integrase inhibitory activity. 
Keywords:  4-Oxo-4H-quinolizine-3-carboxylic acid derivatives; HIV-1 integrase; Mg
2+ 
binding; Aryl diketo acids. 
 
Introduction  
Human immunodeficiency virus type 1 (HIV-1) is the major pathogen of the infection of acquired 
immunodeficiency syndrome (AIDS) [1]. In the past two and half decades, various compounds have 
been developed as medicinal candidates for the treatment of HIV infections aiming at one or several 
steps of the HIV-1 life cycle [2-5] such as absorption, entry, fusion, un-coating, reverse transcription, 
integration, transcription and maturation. Owing to the facts that HIV integrase (IN) is the 
indispensable enzyme in the replication of the life cycle for the HIV virus and no cellular homologues 
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are found in humans [6-9], inhibitors targeted selectively at HIV IN are expected to have low 
cytotoxicity and thus development of HIV IN inhibitors has attracted more and more attention.  
To this end, aryl diketoacids compounds have been reported to be the most promising HIV IN 
inhibitors [10-12]. Structurally, this type of HIV IN inhibitors consists of two main domains, namely, a 
diketoacid subunit and an aromatic moiety with one or two arylalkyl substituents. The former serves as 
the pharmaphore and is proposed to sequester the divalent cofactors (Mg
2+) in the IN active site and 
thus block access of a host DNA to the integrase [13,14]. Meanwhile, the aromatic moiety as 
hydrophobic domain, typically an indole or benzene moiety, is responsible for the selectivity to the 
strand transfer (ST) reaction [15,16].  
As part of our continuing efforts directed towards the development of potential HIV-1 integrase 
inhibitors, we have investigated the chemical and electrochemical synthesis of styrylquinolines [17], 
quinoxalones [18,19] and polyhydroxylated aromatics [20,21]. Based on the structural characteristics 
of diketo acid-type compounds and their molecular mechanism as HIV IN inhibitors, very recently, a 
series of 4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylic acids have been designed and synthesized 
by our group (see I, Figure 1) [22]. In view of the fact that the 4-oxo-quinolizine-3-carboxylic acid 
moiety displays high selectivity and binding ability to Mg(II) (KMG-103 and KMG-104, Figure 1) 
[23,24] and other derivatives show antibacterial and antimicrobial activities [25-27], in the present 
work, we further modified the main core via addition of a bulky group, such as an aryl sulfonamido, 
aryl carboxylamido, benzimidazole or benzothiazole chosen as the side hydrophobic chain and placed 
at the C-1 position of the 4-oxo-quinolizine-3-carboxylic acid scaffold. Thus, a series of 4-oxo-
quinolizine-3-carboxylic acid derivatives 8, 9, 12 and 14 were synthesized. Results show that, although 
these compounds could bind Mg
2+ in CH3CN solution, no obvious anti-HIV IN activity is observed. 
 
Figure 1. The design of 4-oxo-quinolizine-3-carboxylic acid derivatives as potential HIV 
IN inhibitors. 
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Results and Discussion  
Synthesis of 4-oxo-4H-quinolizine-3-carboxylic acid derivatives 8, 9, 12 and 14 
The synthesis of 4-oxo-4H-quinolizine-3-carboxylic acid derivatives 8 and 9 is described in Scheme 
1. Ethyl 4-oxo-4H-quinolizine-3-carboxylate (3) was synthesized in good yield starting from 2-methyl-
pyridine according to a literature procedure [24]. Nitration of 3 afforded compound 4, which was 
reduced by Na2S2O4 to generate the key intermediate ethyl 1-amino-4-oxo-4H-quinolizine-3-
carboxylate (5). In the presence of pyridine, compound 5 was treated with sulfonyl chloride or acyl 
chloride to give compounds 6 and 7, respectively. The target 4-oxo-4H-quinolizine-3-carboxylic acids 
8 and 9 were finally obtained after hydrolysis in NaOH/methanol followed by neutralization. During 
the nitration procedure, the speed of addition of nitric acid should be carefully controlled, otherwise, 
the reaction mixture would become red and the amount of by-products increased. In addition, Na2S2O4 
was used to reduce nitro group and generated key intermediate 5, due to the benign reaction conditions 
(usually at room temperature using water as solvent) and simple workup.  
 
Scheme 1. The synthesis of 4-oxo-4H-quinolizine-3-carboxylic acid derivatives 8 and 9. 
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With  3 in hand, we then synthesized benzothiazole- and benzimidazole-substituted 4-oxo-4H-
quinolizine-3-carboxylic acid derivatives 12 and 14. As shown in Scheme 2, reaction of compound 3 
with DMF and POCl3 generated intermediate 10 [24], which reacted with 2-aminothiophenol [28, 29] 
followed by subsequent hydrolysis to generate 1-(benzothiazole-2-yl)-4-oxo-4H-quinolizine-3-
carboxylic acid (12). Similarly, compound 10 underwent oxidative condensation with o-phenylene-
diamine derivatives in nitrobenzene [30] yielded compounds 13a-c, which were hydrolyzed [31] to 
obtain 1-(benzimidazole-2-yl)-4-oxo-4H-quinolizine-3-carboxylic acids 14a-c. It should be pointed out Molecules 2009, 14                                       
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that two benzimidazole isomers were formed for each of 13b-c and 14b-c, that could not be separated 
each other through conventional procedures.  
It is noteworthy that the conditions for the hydrolysis of 11 and 13 were not similar to those used 
for the synthesis of 8 and 9. The reaction proceeded very slowly in the NaOH/MeOH system. For 
example, after 48 hours stirring at room temperature, the reaction mixtures were still slurries and most 
of the starting materials were present in the reaction system. Consequently, KOH in 80% aqueous 
ethanol was used for the synthesis of 12 and 14.  As the reaction proceeded the slurry of the reaction 
mixture turned clear and the products precipitated when 1 mol·L
-1aqueous HCl was added.  
 
Scheme 2 Synthesis of 4-oxo-4H-quinolizine-3-carboxylic acid derivatives 12 and 14. 
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Structural analysis 
 
The structures of all new 4-oxo-4H-quinolizine-3-carboxylic acid derivatives 6-14 were confirmed 
by 
1H-NMR, 
13C-NMR, IR and ESI-MS (or HRMS) spectra. In the 
1H-NMR spectra of ethyl 4-oxo-
4H-quinolizine-3-carboxylates 6, 7, 11, 13, the 4-oxo-4H-quinolizine ring proton signals appeared at 
lower field compared with those of the benzene ring. For example, in the 
1H-NMR spectra of 6b, the 
two doublets at 9.43 ppm and 8.28 ppm were ascribed to the protons at C-5 and C-8 of the 4-oxo-4H-
quinolizine ring, respectively, while the protons at C-6 and C-7 exhibited two double doublets at 7.76 
ppm and 7.29 ppm. The proton at C-2 resided at 7.63 ppm. A high field AB system (7.31 ppm and 7.64 
ppm) corresponded to the signals of the four benzene ring protons. 
 In the 
1H-NMR of target compounds 8, 9, 12, 14a, one sharp singlet in the δ 13.7-14.1 range was 
observed, which disappeared after the D2O exchange and was consequently attributed to the COOH 
proton. For example, the proton signals of the COOH groups of compounds 8a and 14a were located at 
13.7 ppm and 13.8 ppm, respectively. In addition, compound 14a has a strong singlet at δ 13.7 ppm, 
which demonstrated the existence of a N-H proton in the benzimidazole ring. In the 
13C-NMR spectra 
of these compounds one C=O peak at about 166 ppm and one around 159 ppm corresponded to the 
signals of the 3-carboxylic acid and carbonyl groups in the quinolizine rings. The IR spectra of these Molecules 2009, 14                                       
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compounds further support their postulated structures. There were several medium broad bands at 
3,200~3,400 cm
-1 corresponding to O-H and N-H bond and strong bands at 1,690~1,730 cm
-1 due to 
C=O bonds. The mass spectra of compounds 8c, 13b and 14b exhibited a M+2 signal, whose intensity 
was 1/3 of the molecular ion signal, and corresponding to the Cl isotopes in these compounds. 
 
Preliminary investigation of Mg
2+ binding 
 
To elucidate a two-metal inhibition model, very recently, Kawasuji et al [32] performed metal 
titration studies of 2-hydroxy-3-heteroarylacrylic acid derivatives and observed a two-step shift of the 
UV-Vis spectra upon the addition of Mg
2+ if these compounds exhibited HIV-IN inhibitory activity. 
On the contrary, simple change of UV-Vis absorption curves or no shift was found for their mutated 
compounds which do not inhibit HIV integrase. Inspirited by this assumption, preliminary ion binding 
experiments were also carried out by UV-Vis spectroscopy, using compound 14a as an example. Due 
to the low solubility of 14a in water, CH3CN was used to prepare the stock solution for the UV-Vis 
measurements. As shown in Figure 2, for the free compound 14a, two intense absorption bands at 352 
nm and 414 nm were observed in the 320 – 550 nm range. As the Mg
2+ concentration (as perchlorate 
salt) increased, the absorption intensity of the peak at 414 nm first decreased and then the wavelength 
shifted blue to around 402 nm. Figure 3 further demonstrated the selectivity of compound 14a to Mg
2+. 
In the presence of a 100-fold equivalent amount of Na
+ or K
+, no obvious change was observed. 
However, the Mg
2+ induced a blue shift of the absorption curve of compound 14a. Similar behaviors 
were also observed for other divalent metals, including Mn
2+, Co
2+, Cu
2+, Ca
2+ and Ni
2+ (not shown in 
Figure 3). 
 
Figure 2. Changes of UV-vis spectra with 14a in CH3CN on addition of 0-16×10
-6 mol·L
-1 
of [Mg
2+] at 25 °C. 
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The titration experiment of 14a with Mg
2+ further demonstrated that the binding ratio is 1:1, which 
is consistent with that of KMG-103 and KMG-104 to Mg
2+, indicating that the introduction of 
benzimidazole substituent on the C-1 position of the 4-oxo-4H-quinolizine-3-carboxylic acid scaffold 
does not affect its Mg
2+  binding ability. In a word, a two-step shift of the absorption curve of 
compound 14a upon the addition of Mg
2+ was observed, similar to 2-hydroxy-3-heteroaryl acrylic acid 
derivatives reported by Kawasuji et al [32]. These UV-Vis results indicated that our compounds might 
interact with metal ions (Mg
2+) in the active site of HIV IN and thus offer a piece of in vitro indication 
of possible HIV IN inhibitory activity of these new compounds, in spite of no strict demonstration of 
correction between the inhibitory activity and the metal affinity. 
 
Figure 3. UV-Vis absorption spectra of free 14a and 14a in the presence of K
+, Na
+ or 
Mg
2+ ion in CH3CN solution. 
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Conditions: [14a] = 2 × 10
-5 M; [Mg
2+] = [K
+] = [Na
+] = 2×10
-3 M; Black: 14a, blue: Na
+ complex, 
red: K
+ complex, navy: Mg
2+ complex. 
 
HIV integrase inhibitory activities of 4-oxo-4H-quinolizine-3-carboxylic acid derivatives  
 
The target compounds 8,  9,  12,  14 were screened against purified HIV IN to determine any 
potential inhibitory activity. Thus, a synthesized 30 oligonucleotide and a 20 oligonucleotide were 
used as donor DNA and target DNA, respectively, which were purchased from Shanghai Sangon 
Biological Engineering Technology & Services Co. Ltd. The donor DNA was biotinylated at the 5′ end 
(5′ bio-DNA) and immobilized on streptavidin-coated 96-well microtiter plates. To the donor DNA 
streptavidin-coated 96-well microtiter plate were added test sample, 3' digoxygenin-labeled target 
DNA (3' dig-DNA) and recombinant HIV integrase and subjected to incubation in optimized 
condition. 
The plate was further washed with phosphate-buffered saline (PBS) containing 0.1% Tween
®-20 
and anti-digoxigenin-peroxidase (POD, 100 µL) was added to each well. After incubation at 37°C for 
60 min, the plate was washed with PBS containing 0.1% Tween
®-20. The digoxygenin-labeled 
products were visualized by adding a POD substrate, tetramethylbenzidine (TMB). The colorimetric Molecules 2009, 14                                       
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reaction was stopped by addition of 0.5 mol/L H2SO4 (100 µL), and the absorbance was measured at 
450 nm on a microplate reader. The total inhibitory effect (including inhibiting 3′ process reaction and 
strand transfer reaction) were obtained by comparing the absorbance of drug group with control group 
(without test compound). As shown in Table 1, the values of IC50 of these compounds are more than 
100 μg/mL, which mean a low inhibitory activity to HIV integrase. 
The low HIV IN inhibitory activity of these designed 4-oxo-4H-quinolizine-3-carboxylic acid 
derivatives might stem from various cofactors. Structurally, compounds 8, 9, 12 and 14 possess a 
chelating scaffold suitable for binding only one ion. However, a two-metal chelating scaffold to form 
respectively a five-membered and a six-membered system is required according to the two-metal 
coordinating model for diketoacid-type HIV IN inhibitors. Therefore, the selective binding to Mg
2+ is 
not enough, the two-metal binding scaffold is also necessary in the design of diketoacid-type HIV IN 
inhibitors. In addition, an appropriate substituent at appropriate position of the chelating scaffold is 
also essential to ensure potential inhibitory activity.  
 
Table 1. Integrase inhibitory activity data of 4-oxo-4H-quinolizine-3-carboxylic acid derivatives. 
Sample 
Initial concentration 
(μg/mL) 
IC50  
(μg/mL) 
Sample 
Initial concentration 
(μg/mL) 
IC50  
(μg/mL) 
S-y
1 12  0.56  9a  100 -
2 
8a  100 -
2  9b  100 -
2 
8b  100 -
2  12  100 -
2 
8c  100 -
2  14a  100 -
2 
8d  100 -
2  14b  100 -
2 
8e  100 -
2  14c 100  -
2 
1 S-y provided by the Shanghai Institute of Organic Chemistry was used as positive contrast. 
2 “-” indicates that the HIV-IN inhibitory effect was less than 50% at the initial concentration. 
 
Conclusions 
 
Aryl diketoacid-containing compounds were demonstrated to be the most promising HIV IN 
inhibitors. Based on the molecular mechanism of aryl diketoacids as HIV IN inhibitors and the 
selective binding to Mg
2+ of 4-oxo-4H-quinolizine-3-carboxylic acid unit, a series of 4-oxo-4H-
quinolizine-3-carboxylic acid derivatives, substituted by sulfonoamido, carboxylamido, benzimidazole 
and benzothiazole groups, were designed and synthesized as diketoacid bioisosters. Their anti-HIV IN 
activity was evaluated and no obvious inhibitory activities were observed. Based on the present results, 
in the course of our coming works on development of HIV IN inhibitors, we would have a concept that 
new types of HIV IN inhibitors would incorporate a two-metal chelating scaffold and a appreciate 
hydrophobic domain. Moreover, the two-metal chelating scaffold could have an obvious binding 
affinity to Mg
2+.  
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Experimental  
 
General  
 
All melting points (m.p.) were measured with a XT4A electrothermal apparatus equipped with a 
microscope and are uncorrected. Infrared spectra (IR) were recorded as thin films on KBr plates with a 
Bruker IR spectrophotometer and are expressed in v (cm
-1). 
1H- and 
13C-NMR spectra were recorded 
with an AV 400 M Bruker spectrometer (400 MHz 
1H frequency, 100 MHz 
13C frequency). Chemical 
shifts were measured in CDCl3 or DMSO-d6 with TMS as internal reference. The MS spectra (ESI) 
were recorded on a Bruker Esquire 6000 mass spectrometer. HRMS spectra were recorded in the 
negative ion mode using APEX II FT-ICRMS of Bruker Daltonics Inc. All solvents were of 
commercial quality and were dried and purified by standard procedures. Compounds 2, 3, 4, 10 were 
synthesized according to the literature procedure [24]. 
 
General procedure for the synthesis of ethyl 1-(substituted phenylsulfonamido)-4-oxo-4H-quinolizine-
3-carboxylates 6 
 
Compound 4 (1.97 g, 7.5 mmol) was suspended in a 1:1 mixture of methanol and water (100 mL) in 
a 250 mL flask. Na2S2O4 (7.8 g，45 mmol) was then added in one portion at room temperature and the 
mixture was stirred for about 2 hours. After the reaction, the organic compound was extracted three 
times using CH2Cl2 and dried over anhydrous Na2SO4. After filtration of the Na2SO4, the solvent was 
removed under reduced pressure to give 1.0 g (57%) of 5 as a red solid, which was used for the 
following reactions without further purification. The appropriate substituted sulfonyl chloride (3.44 
mmol) in CH2Cl2 (30 mL) was added dropwise to a CH2Cl2 solution (30 mL) containing 5 (3.44 mmol) 
and dry pyridine (0.3 mL). The solution changed from red to dark and TLC showed the formation of 
new compounds with red fluorescence emission. After the reaction, the solution was washed with 
water and the organic layer was dried over anhydrous MgSO4. After filtration of the MgSO4, the 
solvent was removed under reduced pressure and the residue was recrystallized by ethyl acetate to give 
the desired products 6 as yellow solids. 
 
Ethyl 1-phenylsulfonamido-4-oxo-4H-quinolizine-3-carboxylate (6a): Yield 72%. m.p.: 207-209 °C; 
1H-NMR (CDCl3): δ 1.34 (t, 3H, J = 7.1 Hz, CH3), 4.32 (q, 2H, J = 7.1 Hz, OCH2), 7.25 (dd, 1H, J = 
7.7 Hz, J = 5.9 Hz), 7.48~7.91 (m, 8H, Ar-H), 9.42 (d, 1H, J = 7.1 Hz, ); 
13C-NMR (CDCl3): δ 14.4, 
60.9, 105.6, 106.9, 117.3, 122.0, 128.9, 129.3, 130.1, 134.6, 135.5, 138.4, 143.9, 147.2, 154.7, 164.5; 
IR: ν 3491, 3139, 2981, 1734, 1698, 1493 cm
-1; MS (ESI): m/z 370.9 [M - H]
-. 
 
Ethyl 1-p-methylphenylsulfonamido-4-oxo-4H-quinolizine-3-carboxylate (6b): Yield 60%. m.p.: 115-
117 °C; 
1H-NMR (CDCl3): δ 1.31 (t, 3H, J = 7.2 Hz, CH3), 2.45 (s, 3H, PhCH3), 4.30 (q, 2H, J = 7.2 
Hz, CH2), 6.38 (s, 1H, NH), 7.29~7.33 (m, 3H, Ar-H), 7.64(s, 1H, Ar-H), 7.65(d, 2H, J = 7.6 Hz, Ar), 
7.77 (dd, 1H, J = 7.5 Hz, J = 8.0 Hz, Ar-H), 8.28 (d, 1H, J = 8.8 Hz, Ar-H), 9.43 (d, 1H, J = 7.1 Hz); 
13C-NMR (CDCl3): δ 14.6, 21.8, 61.1, 104.9, 108.3, 117.7, 122.9, 128.0, 130.1, 130.1, 135.4, 135.5, Molecules 2009, 14                                       
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141.5, 144.7, 146.9, 155.1, 165.3; IR: ν 3452, 3164, 2972, 1718, 1629, 1490 cm
-1; MS (ESI): m/z 387.0 
[M + H]
+. 
 
Ethyl 1-p-chloro-phenylsulfonamido-4-oxo-4H-quinolizine-3-carboxylate (6c): Yield 73%. m.p.: 210-
212°C; 
1H-NMR (DMSO-d6): δ 1.24 (t, 3H, J = 7.6 Hz, CH3), 4.18 (q, 2H, J = 7.6 Hz, CH2), 7.54 (s, 
1H, Ar-H), 7.55 (dd, 1H, J = 7.2 Hz, J = 6.4 Hz, Ar-H), 7.68 (d, 2H, J = 8.8 Hz, Ar-H), 7.73 (d, 2H, J 
= 8.8 Hz, Ar-H), 7.97-8.05 (m, 2H, Ar-H), 9.29 (d, 1H, J = 7.2 Hz, Ar-H); 
13C-NMR (DMSO-d6): δ 
14.6, 60.3, 103.1, 108.5, 118.7, 122.4, 129.7, 129.9, 130.0, 136.6, 138.0, 138.6, 140.1, 146.0, 154.0, 
164.5; IR: ν 3445, 3155, 2972, 1715, 1494 cm
-1; MS (ESI): m/z 404.9 [M -1]
-, 428.8 [M + Na]
+. 
 
Ethyl 1-p-methyloxyphenylsulfonamido-4-oxo-4H-quinolizine-3-carboxylate  (6d):  Yield 92%. m.p.: 
236-238°C; 
1H NMR (DMSO-d6): δ 1.19 (t, 3H, J = 6.9 Hz, CH3), 3.82 (s, 3H, OCH3), 4.11 (q, 2H, J = 
7.0, CH2), 7.06 (d, 2H, J = 8.6, Ar-H), 7.49-7.51 (m, 2H, Ar-H), 7.60 (d, 2H, J = 8.6 Hz, Ar-H), 7.90-
8.01 (m, 2H, Ar-H), 9.24 (d, 1H, J = 7.2 Hz, Ar-H), 9.58 (s, 1H, NH); 
13C NMR (DMSO-d6): δ 14.5, 
56.1, 60.4, 103.2, 109.1, 114.9, 118.7, 122.5, 129.8, 129.9, 130.6, 136.3, 140.3, 146.0, 154.1, 163.2, 
164.6; IR: ν 3442, 3170, 2927, 1716, 1650, 1494 cm
-1; MS (ESI): m/z 424.9 [M+Na]
+. 
 
Ethyl 1-p-nitrophenylsulfonamido-4-oxo-4H-quinolizine-3-carboxylate  (6e):  Yield: 76%. m.p.: 265-
267°C; 
1H-NMR (DMSO-d6): δ 1.15 (t, 3H, J = 7.2 Hz, CH3), 4.1 (q, 2H, J = 7.2 Hz, CH2), 7.51 (s, 
1H, Ar-H), 7.49-7.53 (m, 1H, Ar-H), 7.94-7.98 (m, 4H, Ar-H), 8.39 (d, 2H, J = 8.8 Hz, Ar-H), 9.27 (d, 
1H, J = 7.2 Hz, Ar-H), 10.20 (s, 1H, NH); 
13C-NMR (DMSO-d6): δ 14.5, 60.4, 103.1, 108.0, 118.8, 
122.2, 125.0, 129.4, 130.1, 136.8, 140.1, 144.8, 145.8, 150.4, 154.1, 164.6; IR: ν 3446, 3204, 2981, 
1727, 1627, 1497, 1233 cm
-1; MS (ESI): m/z 439.9 [M + Na]
+. 
 
General procedure for the synthesis of 1-(substituted phenylsulfonamido)-4-oxo-4H-quinolizine-3-
carboxylic acids 8 
 
To a suspension of 6 (1.2 mmol) in methanol (15 mL) was added 3 mol/L of NaOH (0.9 mL). The 
reaction mixture was stirred overnight, followed by evaporation of the solvent under reduced pressure. 
The remaining solid was dissolved in water (20 mL) and the clear solution was acidified with 1 mol/L 
HCl to pH 1. The resulting suspension was filtered and dried under vacuum over P2O5 to give 
yellowish solids. 
 
1-Phenylsulfonamido-4-oxo-4H-quinolizine-3-carboxylic acid (8a): Yield 82%. m.p.: 245-247°C; 
1H- 
NMR (DMSO-d6): δ 7.51-7.55 (m, 2H, Ar-H), 7.63-7.66 (m, 5H, Ar-H), 8.00-8.09 (m, 2H, Ar-H), 9.29 
(d, 1H, J = 7.2 Hz, Ar-H), 10.05 (s, 1H, NH), 13.71 (s, 1H, COOH); 
13C-NMR (DMSO-d6): δ 103.7, 
113.0, 120.2, 122.9, 127.6, 129.8, 133.8, 136.9, 138.6, 138.9, 145.0, 158.9, 165.6; IR: ν 3441, 3293, 
3116, 1727, 1616, 1495, 1446, 1365, 1327, 1159 cm
-1; MS (ESI): m/z 344.9 [M + H]
+, 366.9 [M + 
Na]
+. 
 
1-p-Methylphenylsulfonamido-4-oxo-4H-quinolizine-3-carboxylic acid (8b): Yield 75%. m.p.: > 300 
°C; 
1H-NMR (DMSO-d6): δ 2.35 (s, 3H, CH3), 7.33 (d, 2H, J = 8.1 Hz, Ar-H), 7.54 (d, 2H, J = 8.1 Hz, Molecules 2009, 14                                       
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Ar-H), 7.64 (dd, 1H, J = 7.0 Hz, Ar-H), 7.67 (s, 1H, Ar-H), 8.03 (dd, 1H, J = 7.2 Hz, J = 8.4 Hz, Ar-
H), 8.11 (d, 1H, J = 8.8 Hz, Ar-H), 9.29 (d, 1H, J = 7.1 Hz, Ar-H);
 13C-NMR (DMSO-d6): δ 21.5, 
103.7, 113.3, 120.2, 123.0, 127.6, 129.8, 130.2, 136.2, 136.8, 138.5, 144.1, 145.0, 158.9, 165.7; IR: ν 
3265, 3071, 1725, 1619, 1492, 1448, 1292, 1160, 816 cm
-1; HRMS: m/z calcd for C17H13 N 2O5S: 
357.0551; found: 357.0550. 
 
1-p-Chlorophenylsulfonamido-4-oxo-4H-quinolizine-3-carboxylic acid (8c): Yield 79%. mp > 300°C; 
1H-NMR (DMSO-d6): δ 7.65-7.72 (m, 6H, Ar-H), 8.09-8.15 (m, 2H, Ar-H), 9.36 (d, 1H, J = 7.1 Hz, 
Ar-H), 10.22 (s, 1H, NH), 13.70 (s, 1H, OH); 
13C-NMR (DMSO-d6): δ 103.7, 112.7, 120.3, 122.9, 
129.6, 129.9, 129.9, 137.0, 137.8, 138.5, 138.6, 145.0, 158.9, 165.7; IR: ν 3446, 3265, 2924, 1720, 
1489, 1163 cm
-1; MS (ESI): m/z 376.9 [M-H]
-. 
 
1-p-Methoxyphenylsulfonamido-4-oxo-4H-quinolizine-3-carboxylic acid ( 8d):  Yield 86%. mp > 
300°C; 
1H-NMR (DMSO-d6): δ 3.79 (s, 3H, CH3), 7.03 (d, 2H, J = 8.8 Hz, Ar-H), 7.57 (d, 2H, J = 8.8 
Hz, Ar-H), 7.65 (dd, 1H, J = 10.0 Hz, J = 7.2 Hz, Ar-H), 7.68 (s, 1H, Ar-H), 8.03 (dd, 1H, J = 8.6 Hz, 
J = 7.0, Ar-H), 8.10 (d, 1H, J = 8.8Hz, Ar-H), 9.29 (d, 1H, J = 7.2Hz, Ar-H), 9.86 (s, 1H, NH); 
13C- 
NMR (DMSO-d6): δ 56.2, 103.7, 113.3, 114.9, 120.2, 123.0, 129.7, 129.8, 130.5, 136.8, 138.6, 145.1, 
158.9, 163.3, 165.7; IR: ν 3248, 2918, 2849, 1724, 1618, 1597, 1496, 1450, 1294, 1157, 836 cm
-1; MS 
(ESI): m/z 375.0 [M+H]
+. 
 
1-p-Nitrophenylsulfonamido-4-oxo-4H-quinolizine-3-carboxylic acid (8e): Yield 82%; mp > 300°C; 
1H-NMR (DMSO-d6): δ 7.60-7.80 (m, 1H, Ar-H), 7.73 (s, 1H, Ar-H), 7.94 (d, 2H, J = 8.0 Hz, Ar-H), 
8.02-8.05 (m, 2H, Ar-H), 8.35 (d, 2H, J = 8.0 Hz, Ar-H), 9.32 (d, 1H, J = 6.4 Hz, Ar-H), 10.49 (s, 1H, 
NH), 13.68 (s, 1H, OH); 
13C-NMR (DMSO-d6): δ 103.8, 112.3, 120.3, 122.6, 125.1, 129.3, 129.9, 
137.2, 138.6, 144.7, 144.8, 150.4, 158.9, 165.7; IR: ν 3454, 3234, 3082, 1715, 1488, 1167, 786 cm
-1; 
MS (ESI): m/z 387.8 [M-H]
-. 
 
General procedure for the synthesis of 7a,b 
 
To a solution of 3,4,5-trimethoxylbenzoic acid or 3,4-dimethoxycinnamic acid (4 mmol) in ether 
(20 mL) was added PCl5 (20 mL) in one portion. The reaction mixture was heated to reflux for about 4 
hours and then cooled to room temperature. After maintaining in a refrigerator for about 1 hour, a 
white precipitate formed which was filtered and recrystallized from cold ether to give the 
corresponding carboxylic chloride. The newly-synthesized acyl chloride dissolved in CH2Cl2 (20 mL) 
was added dropwise to a mixture of compound 5 (3 mmol) and triethylamine (3 mmol) in CH2Cl2 (20 
mL). The reaction solution was stirred overnight at room temperature. After the reaction, the solution 
was washed with water and the organic layer was dried over anhydrous MgSO4. After filtration of the 
MgSO4, the solvent was removed under reduced pressure and the residue was purified by 
recrystallization from ethyl acetate to give 7a or 7b as a yellow solid. 
 
Ethyl 1-(3,4,5-trimethoxyphenylcarbonylamino)-4-oxo-4H-quinolizine-3-carboxylate (7a): Yield 40%; 
mp 93°C; 
1H-NMR (CDCl3): δ 1.29 (t, 3H, J = 7.2 Hz, CH3), 3.92 (s, 3H, OCH3), 3.95 (s, 6H, OCH3), Molecules 2009, 14                                       
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4.26 (q, 2H, J = 7.2 Hz, OCH2), 7.11 (dd, 1H, J = 6.8 Hz, J = 7.2 Hz, Ar-H), 7.39 (s, 2H, Ph-H), 7.57 
(dd, 1H, J = 8.8 Hz, J = 6.8 Hz, Ar-H), 7.66 (d, 1H, J = 8.8 Hz, Ar-H), 8.08 (s, 1H, Ar-H), 8.66 (bs, 
1H, NH), 9.17 (d, 1H, J = 7.2 Hz, Ar-H);
 13C-NMR (CDCl3): δ = 14.4, 56.4, 60.9, 61.0, 105.1, 105.1, 
110.6, 116.9, 122.0, 128.4, 129.4, 134.2, 140.2, 141.5, 143.7, 153.3, 154.9, 165.3, 166.9; IR: ν 3462, 
3328, 2939, 1720, 1678, 1587, 1487, 1336, 1216, 1126, 1009, 772 cm
-1; MS (ESI): m/z 449.0 [M + 
Na]
+. 
 
Ethyl 1-[3-(3,4-dimethoxyphenyl)acrylamido]-4-oxo-4H-quinolizine-3-carboxylate ( 7b): Yield 85%; 
m.p.: 105-107°C; 
1H-NMR (DMSO-d6): δ 1.30 (t, 3H, J = 7.2 Hz, CH3), 3.81 (s, 3H, OCH3), 3.83 (s, 
3H, OCH3), 4.26 (q, 2H, J = 7.2 Hz, CH2), 6.81 (d, 1H, J = 15.6 Hz, CH=CH), 7.03 (d, 1H, J = 8.4 Hz, 
Ar-H), 7.21 (d, 1H, J = 8.4 Hz, Ar-H), 7.26 (s, 1H, Ar-H), 7.51 (dd, 1H, J = 6.4 Hz, J = 7.2 Hz, Ar-H), 
7.55 (d, 1H, J = 15.6 Hz, Ar-H), 7.86 (d, 1H, J = 8.8 Hz, Ar-H), 7.96 (dd, 1H, J = 7.2 Hz, J = 8.0 Hz, 
Ar-H), 8.26 (s, 1H, Ar-H), 9.30 (d, 1H, J = 7.2 Hz, Ar-H), 9.89 (s, 1H, NH); 
13C-NMR (DMSO-d6): δ 
14.8, 55.9, 56.0, 60.5, 103.7, 110.6, 111.1, 112.2, 118.2, 119.4, 122.3, 122.4, 127.9, 129.8, 135.8, 
139.0, 141.1, 143.1, 149.4, 150.9, 154.1, 165.3, 165.9; IR: ν 3436, 3226, 2935, 1702, 1677, 1595, 
1491, 1377, 1236, 1114, 1026, 768 cm
-1; MS (ESI): m/z 445.0 [M + Na]
+. 
 
General procedure for the synthesis of 9a,b  
 
To a suspension of 7a or 7b (0.5 mmol) in 80% methanol (20 mL) was added NaOH (5 mmol). The 
reaction mixture was heated to reflux till the starting 7a or 7b disappeared according to monitoring by 
TLC. After evaporation of the solvent under reduced pressure, the remaining solid was dissolved in 
water (20 mL) and the clear solution was acidified with 1 mol/L HCl to pH 1 and the resulting 
suspension extracted with CH2Cl2. The combined organic layer was dried over anhydrous MgSO4 
followed by filtration. The desired 9a or 9b were finally obtained as solids by column chromatography 
(eluents: CH3OH/CHCl3 = 1:30) 
 
1-(3,4,5-Trimethoxyphenylcarbonylamino)-4-oxo-4H-quinolizine-3-carboxylic acid  (9a):  Yield 92%; 
m.p.: 280-282°C; 
1H-NMR (DMSO-d6): δ 3.67 (s, 3H, OCH3), 3.80 (s, 6H, OCH3), 7.33 (s, 2H, Ar-H), 
7.64 (dd, 1H, J = 7.2 Hz, J = 6.8 Hz, Ar-H), 7.94 (d, 1H, J = 8.8 Hz, Ar-H), 8.02 (dd, 1H, J = 6.8 Hz, J 
=8.8 Hz, Ar-H ), 8.29 (s, 1H, Ar-H), 9.30 (d, 1H, J = 7.2 Hz, Ar-H), 10.29 (s, 1H, NH), 13.96 (s, 1H, 
COOH);
 13C-NMR (DMSO-d6): δ 56.6, 60.6, 103.9, 105.9, 115.2, 105.9, 115.2, 120.2, 123.3, 129.1, 
129.7, 136.6, 138.2, 141.0, 143.0, 153.2, 159.0, 166.1, 166.5; IR: ν 3440, 3115, 2924, 2853, 1696, 
1657, 1615, 1587, 1496, 1453, 1364, 1292, 1123 cm
-1; MS (ESI): m/z 397.0 [M - H]
-. 
 
1-(3,4-Dimethoxystyrylcarboxylamino)-4-oxo-4H-quinolizine-3-carboxylic acid (9b): Yield 91%; m.p.: 
306-308°C; 
1H-NMR (DMSO-d6): δ 3.82 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 6.84 (d, 1H, J = 16.0 Hz, 
CH=CH), 7.03 (d, 1H, J = 8.4 Hz, Ar-H), 7.23 (d, 1H, J = 8.4 Hz, Ar-H), 7.27 (s, 1H, Ar-H), 7.58 (d, 
1H, J = 16.0 Hz, Ar-H), 7.70-7.74 (m, 1H, Ar-H), 8.10-8.12 (m, 2H, Ar-H), 8.44 (s, 1H, Ar-H), 9.37 (d, 
1H, J = 7.2 Hz, Ar-H), 10.11 (s, 1H, NH), 14.13 (s, 1H, OH); 
13C-NMR (DMSO-d6): δ 56.0, 56.1, 
103.9, 110.9, 112.4, 115.5, 119.3, 120.0, 122.3, 122.8, 127.9, 136.3, 136.9, 141.4, 142.1, 149.5, 151.1, Molecules 2009, 14                                       
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158.8, 165.8, 166.1; IR: ν 3251, 1728, 1612, 1541, 1515, 1464, 1303, 1266 cm
-1; MS (ESI): m/z 393.1 
[M - H]
-.  
 
 
Synthesis of ethyl 1-benzothiazol-2-yl-4-oxo-4H-quinolizine-3-carboxylate (11) 
 
2-Aminophenthiol (250 mg, 2 mmol) was added to a 50 mL of round flask charged with compound 
10 (490 mg, 2 mmol) and acetic acid (15 mL). The reaction mixture was heated to reflux for about one 
hour till TLC confirmed that the reaction had finished. After removal of the solvent, the residue was 
recrystallized from ethyl acetate to offer a needle-like yellow solid. Yield：65%；m.p.: 199-200 °C; 
1H-NMR (DMSO-d6): δ 1.35 (t, 3H, J = 7.1 Hz, CH2CH3), 4.32 (q, 2H, J = 7.1 Hz, CH2CH3), 7.48 (t, 
1H, J = 7.6 Hz, Ar-H), 7.57 (t, 1H, J = 7,6 Hz, Ar-H), 7.70 (t, 1H, J = 7.2 Hz), 8.07 (d, 1H, J = 8.0 Hz, 
Ar-H), 8.15 (d, 1H, J = 8.0 Hz, Ar-H), 8.25 (t, 1H, J = 7.6 Hz, Ar-H), 8.75 (s, 1H, Ar-H), 9.47 (d, 1H, 
J = 7.2 Hz, Ar-H), 9.59 (d, 1H, J = 8.0 Hz, Ar-H); 
13C-NMR (DMSO-d6): δ 15.2, 61.2, 105.0, 106.0, 
120.0, 122.8, 123.3, 124.9, 126.1, 127.5, 131.3, 134.2, 139.4, 142.9, 144.6, 154.3, 154.7, 165.4, 165.9; 
IR: v 1736, 1670, 1623, 1583, 1496, 1222, 1133, 780 cm
-1; MS (ESI): m/z 373 [M + Na]
+. 
 
Synthesis of 1-benzothiazol-2-yl-4-oxo-4H-quinolizine-3-carboxylic acid (12) 
 
KOH (765 mg, 13.7 mmol) dissolved in water (6 mL) was added to a 100 mL round flask charged 
with compound 11 (480 mg, 1.37 mmol) and ethanol (24 mL). The reaction mixture was heated to 
reflux for about four hours till TLC confirmed that the reaction had finished. After removal of the 
solvent, the residue was re-dissolved in water (30 mL) and then acidified to pH 2. The product was 
extracted three times with CH2Cl2 (50 mL) and the combined organic layer was dried over anhydrous 
MgSO4. After filtration of the MgSO4, the solvent was removed under reduced pressure and the 
residue was purified by recrystallization from chloroform/petroleum ether to generate 12 as a yellow 
solid. Yield 68%. m.p.: >300 °C; 
1H-NMR (CDCl3): δ 7.32 (dd, 1H, J = 7.6 Hz, J = 7.2 Hz, Ar-H), 
7.64-7.67 (m, 2H, Ar-H), 7.81-7.91(m, 2H, Ar-H), 7.95 (d, 1H, J = 8.0 Hz, Ar-H), 8.78 (d, 1H, J = 4.8 
Hz), 9.21 (s, 1H, Ar-H), 9.43 (d, 1H, J = 7.2 Hz, Ar-H), 13.95 (s, 1H, COOH); 
13C-NMR (DMSO-d6): 
δ 110.2, 113.2, 119.9, 120.6, 122.6, 123.3, 127.6, 128.3, 130.7, 137.3, 138.3, 138.7, 147.7, 151.4, 
152.4, 163.8, 165.7; IR: v 1750, 1611, 1564, 1453 cm
-1; MS (ESI): m/z 345.0 [M + Na]
+, 361.0 [M + 
K]
+. 
 
General procedure for the synthesis of compounds 13a-c 
 
To a 50 mL of round flask charged with phenylenediamine derivative (1 mmol) and nitrobenzene 
(10 mL) was added compound 10 (245 mg,1 mmol) and then the solution was slowly heated to 100 °C. 
After 1 h stirring, the reaction mixture was further heated to 150 °C and stirred till TLC showed the 
absence of starting 10. The solution was cooled to room temperature and directly loaded onto a silica 
column for chromatographic purification. The eluents were first petroleum ether and then ethyl 
acetate/petroleum ether (1:2). After the nitrobenzene was eluted out, CHCl3/CH3OH was used to elute 
the corresponding 13a-c.  Molecules 2009, 14                                       
 
 
880
Ethyl 1-(1H-benzimidazol-2-yl)-4-oxo-4H-quinolizine-3-carboxylate (13a): Yield 85 %. m.p.: 194-195 
°C; 
1H-NMR (CDCl3): δ 1.20 (t, 3H, J = 7.2 Hz, OCH2CH3), 4.12 (q, 2H, J = 7.2 Hz, OCH2CH3), 7.21 
(t, 1H, J = 7.2 Hz, Ar-H), 7.31~7.36 (m, 2H, Ar-H), 7.67~7.75 (m, 3H, Ar-H), 8.56 (s, 1H, Ar-H), 8.94 
(d, 1H, J = 8.9 Hz, Ar-H), 9.30 (d, 1H, J = 7.2 Hz), 11.5 (br, 1H, NH); 
13C-NMR (CDCl3): δ 14.2, 
61.1, 104.8, 105.2, 117.7, 122.9, 124.8, 129.6, 135.6, 141.1, 144.6, 148.8, 155.2, 165.3; IR: v 1725, 
1678, 1624, 1538 cm
-1; MS (ESI): m/z 334 [M+1], 356 [M + Na]
+. 
 
Ethyl 1-(5(6)-chloro-1H-benzimidazol-2-yl)-4-oxo-4H-quinolizine-3-carboxylate ( 13b): Yield 83 %; 
m.p.: 216-217 °C; 
1H-NMR (CDCl3): δ 1.18 (t, 3H, J = 7.2 Hz, OCH2CH3), 4.10 (q, 2H, J = 7.2 Hz, 
OCH2CH3), 7.23-7.29 (m, 2H, Ar-H), 7.63-7.76 (m, 3H, Ar-H), 8.57 (s, 1H, Ar-H), 9.04 (d, 1H, J = 
8.8 Hz, Ar-H), 9.33 (d, 1H, J = 4.8 Hz, Ar-H), 11.8 (br, 1H, NH); 
13C-NMR (CDCl3): δ 14.1, 61.0, 
104.4, 104.9, 117.9, 123.3, 124.7, 128.3, 129.6, 135.8, 141.1, 144.5, 150.0, 155.1, 165.1; IR: v 3444, 
3219, 1730, 1644, 1488, 1106 cm
-1; MS (ESI): m/z 366 [M-1]
-. 
 
Ethyl 1-(5(6)-methoxy-1H-benzimidazol-2-yl)-4-oxo-4H-quinolizine-3-carboxylate (13c): Yield 88%; 
m.p.: 234-236 °C; 
1H-NMR (CDCl3): δ 1.20 (t, 3H, J = 7.2 Hz, OCH2CH3), 3.89 (s, 3H, OCH3), 4.13 
(q, 2H, J = 7.2 Hz, OCH2CH3), 6.95 (d, 1H, J = 8.8, Ar-H), 7.21-7.71 (m,. 3H, Ar-H), 8.24 (d, 1H, J = 
8.0 Hz, Ar-H), 8.54 (s, 1H, Ar-H), 8.95 (d, 1H, J = 8.8 Hz, Ar-H), 9.30 (d, 1H, d, J = 7.2 Hz, Ar-H); 
13C-NMR (CDCl3): δ 165.36, 156.81, 155.19, 144.55, 140.98, 135.40, 134.56, 129.53, 129.30, 124.83, 
123.49, 117.66, 105.13, 105.08, 61.05, 55.85, 14.18; IR: v 3435, 1723, 1615, 1450 cm
-1; MS (ESI): m/z 
362 [M-1]
-. 
 
General procedure for the synthesis of compounds 14a-c 
 
To a 100 mL of round flask charged with compound 13 (1 mmol) and ethanol (20 mL) was added 
KOH (560 mg, 10 mmol) dissolved in water (5 mL). The reaction mixtures were heated to reflux till 
TLC confirmed that the reactions had finished. After removal of the solvent, the residue was re-
dissolved in water (20 mL) and then acidified to pH 2. The resulting suspensions were filtered, dried 
and purified by column chromatography (eluents: CHCl3/CH3OH) to obtain corresponding 14a-c as 
yellow solids. 
 
1-(1H-Benzimidazol-2-yl)-4-oxo-4H-quinolizine-3-carboxylic acid (14a): Yield 20 %. m.p.: >300 °C; 
1H-NMR (DMSO-d6): δ 7.23 (m, 2H, Ar-H), 7.53 (m, 1H, Ar-H), 7.70 (m, 1H, Ar-H), 7.79 (t, 1H, J = 
6.8 Hz, Ar-H), 8.28 (t, 1H, J = 5.6 Hz, Ar-H), 8.97 (s, 1H, Ar-H), 9.47 (d, 1H, J = 6.8 Hz, Ar-H), 9.85 
(d, 1H, J = 9.2 Hz, Ar-H), 13.14 (s, 1H, NH), 13.75 (s, 1H, COOH); 
13C-NMR (DMSO-d6): δ 104.6, 
107.0, 111.8, 119.2, 120.6, 122.3, 123.3, 125.8, 130.2, 134.8, 138.1, 139.4, 143.9, 144.2, 149.1, 159.4, 
166.1; IR: v 1705, 1612, 1497, 1443 cm
-1; HRMS: m/z calcd for C17H10N3O3: 304.0718; found: 
304.0727. 
 
1-(5(6)-Chloro-1H-benzimidazol-2-yl)-4-oxo-4H-quinolizine-3-carboxylic acid  (14b): Yield: 35 %. 
m.p.>300 °C; 
1H-NMR (DMSO-d6) δ: 7.43 (dd, 1H, J = 8.4 Hz, J = 1.6 Hz, Ar-H), 7.74 (d, 1H, J = 8.4 
Hz, Ar-H), 7.78 (s, 1H, Ar-H), 7.79 (t, 1H, J = 7.2 Hz, Ar-H) , 8.25 (t, 1H, J = 7.6 Hz, Ar-H), 8.89 (s, Molecules 2009, 14                                       
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1H, Ar-H), 9.09 (d, 1H, J = 8.8 Hz, Ar-H), 9.45 (d, 1H, J = 7.2 Hz, Ar-H); 
13C-NMR (DMSO-d6) δ: 
101.9, 104.9, 114.6, 116.3, 120.7, 124.9, 125.2, 129.2, 130.6, 133.9, 136.0, 138.9, 141.7, 144.2, 148.6, 
158.6, 165.7; IR: v 3434, 1718, 1612, 1499 cm
-1; MS (ESI) m/z: 338 [M-1]
-. 
 
1-(5(6)-Methoxy-1H-benzimidazol-2-yl)-4-oxo-4H-quinolizine-3-carboxylic acid  (14c): Yield 45 %. 
m.p.: >300 °C; 
1H-NMR (DMSO-d6): δ 3.86 (s, 3H, OCH3), 7.06 (dd, 1H, J = 8.4 Hz, J = 2.0 Hz, Ar-
H), 7.21 (d, 1H, J = 2.0 Hz, Ar-H), 7.66 (d, 1H, J = 8.8 Hz, Ar-H), 7.80 (t, 1H, J = 6.8 Hz, Ar-H), 8.26 
(t, 1H, J = 8.4 Hz,Ar-H), 8.88 (s, 1H, Ar-H), 9.09 (d, 1H, J = 8.8 Hz, Ar-H), 9.48 (d, 1H, J = 7.2 Hz, 
Ar-H); 
13C-NMR (DMSO-d6):  δ 165.76, 158.73, 157.63, 146.81, 144.11, 141.15, 138.64, 136.03, 
130.49, 129.85, 125.03, 120.65, 115.89, 114.55, 104.84, 103.86, 97.09, 56.24; IR: v 3415, 1728, 1618 
cm
-1; MS (ESI): m/z 334 [M-1]
-. 
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